
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health is set to experience continued growth in both revenue and EBITDA, driven by strong performance in its Pharmacy Solutions and Provider Services segments. The company's efficient operations and focus on high-need and high-cost patient populations position it as a leader in the industry, and its expansion into all 50 states provides ample opportunity for future growth. Additionally, the company's excellent balance sheet and solid cash flow indicate strong financial health, making it an attractive investment option.
Bears say
BrightSpring Health is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services, which recently reported negative financial results; despite strong momentum in Specialty and Infusion and a healthy pipeline of drugs converting to generic in the future, BTSG's Pharmacy Solutions revenue and adjusted EBITDA showed underperformance, as it missed expectations by -0.3% and -2.6%, respectively, and the company's 1Q26 gross margin of 13.3% was below Stephens' estimate of 14.5%.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares